Trial Profile
Observational Study of Osteoblast Activity in Velcade(Bortezomib) IV Treated Multiple Myeloma Patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary)
- Indications Multiple myeloma
- Focus Biomarker; Pharmacodynamics
- Sponsors Janssen
- 09 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Dec 2009 New trial record